Skip to main content

Table 3 Incidence of first serious morbidity event, death, loss to follow-up and attrition following ART initiation, by time on ART; CMSDS, Abidjan, Côte d’Ivoire, 2003-2008

From: Incidence of serious morbidity in HIV-infected adults on antiretroviral therapy in a West African care centre, 2003-2008

  Duration of follow-up (months) P **
  0 to 12 12 to 72  
Serious morbidity      
 Overall      10-4
  Events, n (Time at risk, PY) 111 (698) 81 (972)  
  Incidence/100 PY (95% CI) 15.9 (13.0-18.9) 8.3 (6.5-10.2)  
 WHO stage III or IV events      4.10-3
  Events, n (Time at risk, PY) 28 (734) 20 (1214)  
  Incidence/100 PY (95% CI) 3.8 (2.4-5.2) 1.7 (0.9-2.4)  
 ANRS grade 3 or 4      6.10-3
  Events number (Time at risk, PY) 26 (740) 19 (1233)  
  Incidence/100 PY (95% CI) 3.5 (2.2-4.9) 1.5 (0.8-2.2)  
 Confirmed malaria      0.80
  Events number (Time at risk, PY) 24 (737) 39 (1124)  
  Incidence/100 PY (95% CI) 3.3 (2.0-4.6) 3.5 (2.4-4.6)  
 Other serious events*      5.10-3
  Events number (Time at risk, PY) 22 (741) 15 (1268)  
  Incidence/100 PY (95% CI) 3.0 (1.7-4.2) 1.2 (0.6-1.8)  
Death      10-4
  Events number (Time at risk, PY) 32 (751) 15 (1324)  
  Incidence/100 PY (95% CI) 4.3 (2.8-5.7) 1.1 (0.6-1.7)  
Lost to follow-up      10-2
  Events number (Time at risk, PY) 61 (778) 67 (1371)  
  Incidence/100 PY (95% CI) 7.8 (5.9-9.8) 4.9 (3.7-6.1)  
Attrition      10-4
  Events number (Time at risk, PY) 95 (769) 80 (1369)  
  Incidence/100 PY (95% CI) 12.4 (9.9-14.8) 5.8 (4.6-7.1)  
  1. PY, Person-Years; CI, Confidence Interval; ART, Antiretroviral Therapy; WHO, World Health Organization; ANRS, Agence Nationale de Recherche sur le SIDA et les Hépatites Virales.
  2. *: non-classifying events with ≥ one day at hospital, or leading to death.
  3. Lost to follow-up: patients whose last contact with the study center was prior to 31 Dec 2008, and who were not found to be deceased, alive, or transferred out up to August 31st 2009.
  4. **: univariable Poisson models.